Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:10085143rdf:typepubmed:Citationlld:pubmed
pubmed-article:10085143lifeskim:mentionsumls-concept:C0173695lld:lifeskim
pubmed-article:10085143lifeskim:mentionsumls-concept:C0205341lld:lifeskim
pubmed-article:10085143lifeskim:mentionsumls-concept:C0332197lld:lifeskim
pubmed-article:10085143lifeskim:mentionsumls-concept:C0332281lld:lifeskim
pubmed-article:10085143lifeskim:mentionsumls-concept:C1421455lld:lifeskim
pubmed-article:10085143lifeskim:mentionsumls-concept:C0015295lld:lifeskim
pubmed-article:10085143lifeskim:mentionsumls-concept:C1517880lld:lifeskim
pubmed-article:10085143lifeskim:mentionsumls-concept:C1167622lld:lifeskim
pubmed-article:10085143lifeskim:mentionsumls-concept:C0392756lld:lifeskim
pubmed-article:10085143lifeskim:mentionsumls-concept:C2700640lld:lifeskim
pubmed-article:10085143lifeskim:mentionsumls-concept:C0871161lld:lifeskim
pubmed-article:10085143pubmed:issue13lld:pubmed
pubmed-article:10085143pubmed:dateCreated1999-4-29lld:pubmed
pubmed-article:10085143pubmed:abstractTextThe very low density lipoprotein receptor (VLDLR) binds, among other ligands, the Mr 40,000 receptor-associated protein (RAP) and a variety of serine proteinase-serpin complexes, including complexes of the proteinase urokinase-type plasminogen activator (uPA) with the serpins plasminogen activator inhibitor-1 (PAI-1) and protease nexin-1 (PN-1). We have analyzed the binding of RAP, uPA.PAI-1, and uPA.PN-1 to two naturally occurring VLDLR variants, VLDLR-I, containing all eight complement-type repeats, and VLDLR-III, lacking the third complement-type repeat, encoded by exon 4. VLDLR-III displayed approximately 4-fold lower binding of RAP than VLDLR-I and approximately 10-fold lower binding of the most C-terminal one of the three domains of RAP. In contrast, the binding of uPA.PAI-1 and uPA.PN-1 to the two VLDLR variants was indistinguishable. Surprisingly, uPA.PN-1, but not uPA.PAI-1, competed RAP binding to both VLDLR variants. These observations show that the third complement-type repeat plays a crucial role in maintaining the contact sites needed for optimal recognition of RAP, but does not affect the proteinase-serpin complex contact sites, and that two ligands can show full cross-competition without sharing the same contacts with the receptor. These results elucidate the mechanisms of molecular recognition of ligands by receptors of the low density lipoprotein receptor family.lld:pubmed
pubmed-article:10085143pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10085143pubmed:languageenglld:pubmed
pubmed-article:10085143pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10085143pubmed:citationSubsetIMlld:pubmed
pubmed-article:10085143pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10085143pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10085143pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10085143pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10085143pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10085143pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10085143pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10085143pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10085143pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10085143pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10085143pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10085143pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10085143pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:10085143pubmed:statusMEDLINElld:pubmed
pubmed-article:10085143pubmed:monthMarlld:pubmed
pubmed-article:10085143pubmed:issn0021-9258lld:pubmed
pubmed-article:10085143pubmed:authorpubmed-author:OkiCClld:pubmed
pubmed-article:10085143pubmed:authorpubmed-author:ChanLLlld:pubmed
pubmed-article:10085143pubmed:authorpubmed-author:MonardDDlld:pubmed
pubmed-article:10085143pubmed:authorpubmed-author:AndreasenP...lld:pubmed
pubmed-article:10085143pubmed:authorpubmed-author:ChristensenAAlld:pubmed
pubmed-article:10085143pubmed:authorpubmed-author:EtzerodtMMlld:pubmed
pubmed-article:10085143pubmed:authorpubmed-author:PetersenH HHHlld:pubmed
pubmed-article:10085143pubmed:authorpubmed-author:EllgaardLLlld:pubmed
pubmed-article:10085143pubmed:authorpubmed-author:MartensenP...lld:pubmed
pubmed-article:10085143pubmed:authorpubmed-author:RettenbergerP...lld:pubmed
pubmed-article:10085143pubmed:issnTypePrintlld:pubmed
pubmed-article:10085143pubmed:day26lld:pubmed
pubmed-article:10085143pubmed:volume274lld:pubmed
pubmed-article:10085143pubmed:ownerNLMlld:pubmed
pubmed-article:10085143pubmed:authorsCompleteYlld:pubmed
pubmed-article:10085143pubmed:pagination8973-80lld:pubmed
pubmed-article:10085143pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:10085143pubmed:meshHeadingpubmed-meshheading:10085143...lld:pubmed
pubmed-article:10085143pubmed:meshHeadingpubmed-meshheading:10085143...lld:pubmed
pubmed-article:10085143pubmed:meshHeadingpubmed-meshheading:10085143...lld:pubmed
pubmed-article:10085143pubmed:meshHeadingpubmed-meshheading:10085143...lld:pubmed
pubmed-article:10085143pubmed:meshHeadingpubmed-meshheading:10085143...lld:pubmed
pubmed-article:10085143pubmed:meshHeadingpubmed-meshheading:10085143...lld:pubmed
pubmed-article:10085143pubmed:meshHeadingpubmed-meshheading:10085143...lld:pubmed
pubmed-article:10085143pubmed:meshHeadingpubmed-meshheading:10085143...lld:pubmed
pubmed-article:10085143pubmed:meshHeadingpubmed-meshheading:10085143...lld:pubmed
pubmed-article:10085143pubmed:meshHeadingpubmed-meshheading:10085143...lld:pubmed
pubmed-article:10085143pubmed:meshHeadingpubmed-meshheading:10085143...lld:pubmed
pubmed-article:10085143pubmed:meshHeadingpubmed-meshheading:10085143...lld:pubmed
pubmed-article:10085143pubmed:meshHeadingpubmed-meshheading:10085143...lld:pubmed
pubmed-article:10085143pubmed:meshHeadingpubmed-meshheading:10085143...lld:pubmed
pubmed-article:10085143pubmed:meshHeadingpubmed-meshheading:10085143...lld:pubmed
pubmed-article:10085143pubmed:meshHeadingpubmed-meshheading:10085143...lld:pubmed
pubmed-article:10085143pubmed:meshHeadingpubmed-meshheading:10085143...lld:pubmed
pubmed-article:10085143pubmed:meshHeadingpubmed-meshheading:10085143...lld:pubmed
pubmed-article:10085143pubmed:year1999lld:pubmed
pubmed-article:10085143pubmed:articleTitleLigand binding properties of the very low density lipoprotein receptor. Absence of the third complement-type repeat encoded by exon 4 is associated with reduced binding of Mr 40,000 receptor-associated protein.lld:pubmed
pubmed-article:10085143pubmed:affiliationDepartment of Molecular and Structural Biology, University of Aarhus, DK-8000 Aarhus C, Denmark.lld:pubmed
pubmed-article:10085143pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:10085143pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:10085143pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10085143lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:10085143lld:pubmed